Exhibit 130 ยท Institutional statement
PATH's Chief Scientific Officer accepts role with FDA agency, CBER
Prior to joining PATH, he was a Vice President of Vaccines and Infectious Disease at Merck Research Laboratories, while serving in key advisory positions with MVI and the Bill & Melinda Gates Foundation.
David C. Kaslow, PATH's chief scientific officer, was named director of the Office of Vaccines Research and Review in FDA's Center for Biologics Evaluation and Research, effective 11 October 2022, succeeding acting director Peter Marks. Before joining PATH in 2012 he was vice president of vaccines and infectious disease at Merck Research Laboratories.
- Source
- PATH
- Date
- 8 September 2022
- Quoted from
- PATH press release of 8 September 2022, paragraph 3 of the biography
- Grade
- Primary record
- Document
- https://www.path.org/our-impact/media-center/paths-chief-scientific-officer-accepts-role-with-fda-agency-cber/
- Accessed
- 2026-11-09
- Cited by
- Findings citing this exhibit